ArticleNAR cancer2025

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

Giuditta Illuzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.